Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) FCF Margin (2020 - 2025)

Fennec Pharmaceuticals filings provide 4 years of FCF Margin readings, the most recent being 43.28% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 2468.0% to 43.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 27.94%, a 8103.0% decrease, with the full-year FY2025 number at 27.94%, down 8469.0% from a year prior.
  • FCF Margin hit 43.28% in Q4 2025 for Fennec Pharmaceuticals, down from 11.98% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 147.01% in Q1 2024 to a low of 332.56% in Q1 2023.
  • Median FCF Margin over the past 3 years was 42.82% (2025), compared with a mean of 56.75%.
  • Biggest five-year swings in FCF Margin: soared 47957bps in 2024 and later plummeted -19635bps in 2025.
  • Fennec Pharmaceuticals' FCF Margin stood at 49.92% in 2023, then surged by 63bps to 18.6% in 2024, then tumbled by -133bps to 43.28% in 2025.
  • The last three reported values for FCF Margin were 43.28% (Q4 2025), 11.98% (Q3 2025), and 38.19% (Q2 2025) per Business Quant data.